In December 2024, nearly 20 medical device companies worldwide completed a new round of financing, with a total amount exceeding 2 billion yuan.
Trends in Medical Device Investment and Financing in 2024Source of the image: Pharma Data Enterprise Edition - Investment Landscape Database
Table 1: Global Investment and Financing Events in December 2024
Source: Pharma Data Enterprise Edition - Investment Landscape DatabaseNote: The exchange rates in the table are calculated based on the exchange rate at the time of financing completion.
Among them, multiple domestic companies completed in DecemberBillion-yuan levelFinancing.On December 3, Chenxin Technology announced the completion of a 200 million yuan B-round financing. This round of financing was led by SDIC Venture Capital, with participation from Sunshine Ronghui and existing shareholder Volcano Stone Investment. The funds will mainly be used for the company's forward-looking product research and development, new product mass production, and global business layout. Chenxin Technology is a provider of precision instruments and automated testing equipment for silicon carbide (SiC) power semiconductors.Chenxin Technology was founded in 2020, and its main products cover the characterization and testing of silicon carbide (SiC), gallium nitride (GaN), and silicon (Si)-based power semiconductor devices. In the field of high-end medical imaging equipment, Chenxin Technology focuses on dual-energy instant-switching CT high-voltage generators and X-ray sources. The company’s long-term R&D investment in CT medical high-voltage generator products is being introduced to leading first-tier manufacturers, with the finalization of mainstream models and small-scale production imminent.On December 5, Wuhan Kaidewei Biotechnology Co., Ltd announced the completion of a nearly 200 million yuan Series B financing round, led by Fir Creek Capital with an investment of 50 million yuan, and followed by Wuhan Gaoke, Hongtai Industrial Finance, Hubei Science Investment, Jiuzhou Tong Chuchang Investment, and other institutions. The funds from this round will be used for the clinical development and market expansion of the company's various products in the field of gynecological cancer diagnosis and treatment.Two original in vitro diagnostic kits developed by Kaidewei have been approved for the second consecutive year to enter the National Medical Products Administration (NMPA) Innovative Medical Device Review Fast-Track, which are expected to facilitate rapid screening and precise diagnosis and treatment of gynecological cancers such as endometrial cancer and cervical cancer, as well as their precancerous lesions. This is set to significantly improve patient accessibility while reducing unnecessary invasive examinations and medical costs.On December 6, EOSVISION announced the completion of a nearly RMB100-million Series A financing round, led by Daotong Investment. This round of financing will be used to accelerate the research and development, clinical trials, international development, registration, and marketing expansion of innovative ophthalmology and regenerative medicine products in the pipeline, including artificial biomimetic cornea, implantable contact lenses, artificial corneal endothelial patches, and artificial dermis.EOSVISION was founded in 2020, focusing on the development of innovative products using novel bio-modified materials for ophthalmic implant medical devices and regenerative medicine devices. Currently, EOSVISION has built three static ISO Class 7 clean production workshops (locally static ISO Class 5) and established a comprehensive quality system according to ISO13485, FDA QSR820, and China's Good Manufacturing Practice for Medical Devices.On December 12, Meidong Huicheng announced the completion of a C++ round of financing worth several hundred million yuan, led by QuDao Asset. The proceeds will be used for the development and operation of consumer healthcare and life science storage pipelines.Meidong Huicheng started in Kunshan, Jiangsu in 2017. It has successfully achieved large-scale commercialization of its CDMO business for minimally invasive surgical instruments and rapidly expanded its operations to encompass the entire fields of IVD and life sciences. Currently, Meidong Huicheng's product pipeline has extended into the consumer healthcare sector, with the potential to ignite a new growth trajectory.On December 13, EOSVISION secured an investment of over 100 million yuan. EOSVISION focuses on the application research of femtosecond lasers in ophthalmic surgery and biomaterials processing, with a long history in optics, optoelectronics, and laser fields.It is reported that EOSVISION has research and development centers in Nanjing and Wuhan. Its first commercial product — a femtosecond laser corneal refractive surgery device — originated from the technology transfer of Wuhan National Optoelectronics Laboratory at Huazhong University of Science and Technology. EOSVISION has obtained more than 10 patents, with additional patents still in the application process, and has basically achieved the domestic production of core technologies and key components for femtosecond laser corneal refractive surgery equipment in China. In the final month of 2024, EOSVISION, having secured financing, is pushing forward the production of seven devices. The first batch of products will be put into use at six well-known ophthalmic hospitals in China before the Spring Festival next year.On December 16, Zhi Tong Technology announced the completion of a nearly 100-million-yuan Series A round of financing. This round of financing was jointly led by Aibo Qing Shi Fund and Shan Lan Capital, with participation from Zero One Ventures, Chongqing Airuilin, and WinX Capital serving as the exclusive financial advisor for this transaction while continuing to oversee subsequent financing. The funds from this round of financing will mainly be used for the research and development, registration, and market promotion of modular products for surgical and ophthalmic applications, as well as the development of complete systems for microscopic surgical visualization.EOSVISION was founded in 2020, with a strong R&D team dedicated to the research and development of key technologies for visual perception and intelligent decision-making in microsurgical scenarios. Focusing on ultra-high-definition stereoscopic vision technology and intelligent human-computer interaction technology as the core product line, the company has established a strategic development plan of "computational imaging + industry application." It aims to become a leader in precision visual imaging technology and a global provider of high-end medical imaging modules, equipment, and digital surgical solutions.On December 17, Vymed Medical completed an over RMB 100 million Series B financing round, invested by a well-known top-tier fund in China, with WinX Capital serving as the exclusive financial advisor. The funds will be used to expand Vymed Medical's multi-pipeline layout in the fields of energy medicine and medical devices, accelerate the production, sales channel expansion, and brand building of core products such as YOUMAGIC®, providing strong financial support for the research, innovation, and market expansion of YOUMAGIC and Vymed Medical.It is reported that this round of financing comes at a critical period for the strategic development of YOUMAGIC and its R&D company, Vbeam Medical. It also coincides with the successful approval of YOUMAGIC® by the NMPA as a Class III medical device. The approval fully demonstrates the safety, reliability, clinical efficacy, and rigorous testing of Vbeam's product technology, marking that YOUMAGIC® has built up a technical barrier and competitive advantage, officially commencing its commercialization journey.On December 21, V-KING MEDICAL announced the successful completion of its C-round financing, raising several hundred million RMB. The round was fully led by Bohua Capital, a well-known investment institution in Liangxi District, Wuxi City. This round of financing will provide strong financial support for V-KING MEDICAL in areas such as product development, market expansion, and international strategic layout.Since its establishment in July 2018, Weike Medical has consistently focused on addressing significant clinical needs in the cardiovascular field, particularly in the area of heart failure and minimally invasive interventions for structural heart disease. With core competencies in research and development, technical services, manufacturing, and sales, the company is committed to building an innovative medical device platform that provides full-cycle cardiovascular solutions, offering advanced products and treatment options to patients and doctors worldwide.▲TextChapterComeSource:Pharmaceutical Intelligence Medical Device▲Please indicate the source above when reprinting.
Disclaimer: This article is for informational purposes only and serves as a reference. It does not constitute any advice on investment or treatment. Please exercise caution and discretion. If the content involves issues related to the work, copyright, or other aspects, to protect the rights and interests of both parties, please contact us, and we will handle it immediately. If any platform reprints this article, they must take responsibility for it themselves. The Medical Device Innovation Network is not responsible for any secondary dissemination caused by reprints.
